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Abstract
The availability of very large number of markers by modern technology makes genome-wide
association studies very popular. The usual approach is to test single-nucleotide polymorphisms
(SNPs) one at a time for association with disease status. However, it may not be possible to detect
marginally significant effects by single-SNP analysis. Simultaneous analysis of SNPs enables detection
of even those SNPs with small effect by evaluating the collective impact of several neighboring
SNPs. Also, false-positive signals may be weakened by the presence of other neighboring SNPs
included in the analysis. We analyzed the North American Rheumatoid Arthritis Consortium data
of Genetic Analysis Workshop 16 using HLasso, a new method for simultaneous analysis of SNPs.
The simultaneous analysis approach has excellent control of type I error, and many of the
previously reported results of single-SNP analyses were confirmed by this approach.

Background
The increase in genome-wide experiments and sequencing of multiple genomes has resulted in the availability
of large data sets for genome-wide association studies
(GWAS) of complex diseases. The usual procedure is to
test these single-nucleotide polymorphisms (SNPs) one
by one for association with the disease status. This
means one will be testing the marginal effect of a SNP on
a disease without consideration of any other interacting
SNPs in the model. This approach will inherently
increase the overall probability of false positives [1].
Because complex diseases arise from many, possibly
interacting, genes from the genome, it would be more

appropriate to study the effect of several genes jointly
rather than testing each of them separately [2]. The
single-SNP analysis may ignore information provided by
a joint distribution [3].
The North American Rheumatoid Arthritis Consortium
(NARAC) data of Genetic Analysis Workshop (GAW) 16
provides an excellent opportunity to analyze simultaneously a very large collection of SNPs for GWAS. We
adopt a recently developed method [4] for the simultaneous analysis of SNPs from the NARAC data. This
method is useful when the number of SNPs is much
greater than the number of individuals in a case-control
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study. The procedure is formulated as a problem of
variable selection in a logistic regression framework by
treating each SNP as a covariate. It attempts to find a
collection of SNPs to obtain the “best” model to explain
the disease status for a specified error rate.

Methods
The NARAC data consists of 868 cases of rheumatoid
arthritis (RA) and 1194 controls. The software program
HLasso [4] was employed for the simultaneous analysis
of SNPs. The program adopts a Bayesian approach for
logistic regression and makes use of the normalexponential-gamma (NEG) probability density function
as the penalty function (see Hoggart et al. [4] for details).
The NEG probability density function has two parameters, a scale parameter g and a shape parameter h. As
both g and h increase such that
2η /g remains a
constant, say l, the NEG converges to the double
exponential distribution with rate parameter l. The
predictors in the logistic regression model are the SNP
genotypes, coded as 0, 1, and 2, corresponding to an
additive model. These coded values are standardized to
have mean zero and unit variance. The procedure
searches for a collection of SNPs for which the posterior
mode is positive. A positive posterior mode indicates a
signal of association that is strong enough to overcome
the prior preference of zero effect, and the corresponding
set of SNPs are declared as significantly associated with
the disease.
Further analysis was done to identify whether the SNPs
declared significant by this method confirms the earlier
findings by single-marker analyses. We examined
whether the markers identified as significant by the
simultaneous approach are in high linkage disequilibrium (LD) with SNPs that are already identified to be
associated with the disease. Particular attempt was made
to test SNPs identified by single-marker analysis on
chromosomes 1, 6, and 9 from other data sets. The
software package Haploview [5] was used to compute
the pair-wise LD for SNPs on the chromosomes.

Results
Chromosomes 1 through 22 were analyzed. Table 1
provides the number of SNPs found to be significant on
each chromosome. From a total of 531,689 SNPs, 2627
SNPs were found to be significantly associated with the
disease by this procedure, yielding an upper bound of
0.4941% for the empirical type I error rate.
The logistic regression model, logit(P(affected)) =
n
β 0 + ∑ i =1 β i (SNP ) i , was employed for the analyses.
When a marker is declared significant, the estimate β̂ i
of b provides an estimate of the effect of that marker on
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the affection status of the disease. An estimate of the
odds ratio (OR) for the disease is exp( β̂ i ). This means
that OR > 1 if β̂ i > 0, and OR < 1 if the β̂ i < 0. Therefore,
when β̂ i > 0, the allele coded as “1” increases the disease
risk; and when β̂ i < 0, the allele coded as “1” has a
protective effect and decreases the disease risk. Table 1
also provides the marker with the largest risk effect value
and the marker with the largest protective effect value on
each chromosome.
It is well known that HLA-DRB1 region on chromosome
6 is associated with RA. In the HLA-DRB1 region the
marker rs602875 at position 32.68 Mb was identified to
be significant in our study. By single-SNP analysis of a
different data set, Chang et al. identified the marker
rs1953126 near the TRAF1-C5 region on chromosome 9
to be associated with RA [6]. Also, Plenge et al., through
single SNP analysis, identified the markers rs3761847
and rs2900180 in the same region to be of risk for RA
[7]. In our simultaneous analysis, the marker rs3933326
near the TRAF1-C5 region was identified to be significant, which is in high LD with the markers rs1953126,
rs3761847, and rs2900180. Begovich et al. [8] identified
the marker rs2476601 in the PTPN22 region of
chromosome 1 to be associated with risk for RA. The
simultaneous analysis also identified this marker to be
associated with RA, confirming the earlier findings.

Discussion
n +n ⎞
⎛
The type I error is given by α = 2 − 2Φ ⎜ f ′ n0 n 1 ⎟ ,
0 1 ⎠
⎝
where f’ is the derivative of -log(NEG) at the origin
(which is the derivative of the double exponential
distribution with parameter g = 2η /g at the origin),
n0 is the number of cases, n1 is the number of controls,
and F is the cumulative distribution function of the
standard normal distribution [4]. For our computations,
we set l to be 50 and the shape parameter h to be 0.1, so
that the calculated value of a = 0.025. The simultaneous
analysis identified only 0.4941% of SNPs to be
significantly associated with RA. Because the vast
majority of the SNPs are not associated with RA, this is
a conservative estimate of the empirical type I error.
Comparing this with the nominal level of 0.025, it is
evident that the simultaneous analysis procedure has
excellent control of type I error.

In modeling all SNPs simultaneously, the HLasso
program includes a SNP in the model if it significantly
improves prediction of case-control status beyond that
obtained from SNPs already included in the model [4].
Problems could arise when there are two or more tightly
linked causal markers. In this case, if HLasso chooses
only one marker, its effect could be inflated. For
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Table 1: Number of significant markers identified by the simultaneous analysis and markers with extreme effect sizes

Chromosome number

Number of SNPs

Number of significant SNPs

Markers with largest risk and protective effects
Largest risk effect

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

40929
44090
36690
32628
33612
35574
29244
30990
26128
28331
26477
26365
20242
17951
16166
16460
14027
16450
9236
13843
8051
8205

142
140
138
133
90
82
130
130
125
131
119
129
129
124
121
111
123
123
101
114
102
90

Total

531689

2627

Largest protective effect

Marker

Effect size

Marker

Effect size

rs7519615
rs655783
rs7616866
rs768063
rs344156
rs6935937
rs9632680
rs7006628
rs6478815
rs2388121
rs1879445
rs1146114
rs2323883
rs4296166
rs7183817
rs4238802
rs2880328
rs2303508
rs3810256
rs6513195
rs2823819
rs761917

1.73638
0.91779
202.447
155.04
1.46745
3.06767
96.105
0.577914
154.845
0.777184
123.081
1.43868
4.76091
1.53678
0.814795
0.66247
92.8919
78.2526
1.11899
3.13637
0.971309
1.46745

rs2275864
rs938869
rs9288967
rs6816684
rs6899062
rs1856363
rs4732523
rs2853259
rs1387292
rs1909668
rs7932437
rs7300982
rs9740397
rs4983565
rs3743372
rs4783187
rs9747823
rs1982040
rs10404348
rs6138601
rs1539902
rs17406434

-1.41482
-2.3145
-4.23478
-2.31044
-1.68164
-2.18496
-2.41344
-1.50527
-3.12822
-1.36459
-6.04313
-1.59685
-3.53682
-2.02512
-2.60765
-1.98159
-1.31507
-2.32656
-3.04764
-4.63256
-1.08918
-1.68164

example, the marker rs7616866 on chromosome 3 at
position 64317576 had the largest effect size 202.447,
and was found to be significant. The LD values, D’, of
this marker with the markers rs9812599 at 64315677,
rs7615058 at 64321040, rs6445398 at 64309797, and
rs1860819 at 64323994 are 0.857, 0.769, 1.0, and 0.977,
respectively. When there is high pair-wise LD between
markers, multicollinearity is present, and in such cases it
is not possible to make meaningful statements about
individual effect sizes. However, the overall model is
valid in predicting the disease status of the disease.

was done. There were many significant markers on each
chromosome. We checked whether these markers were
themselves in high LD with each other. Five pairs among
them on chromosome 6 were found to be in high LD, and
none were found on any other chromosomes. It could be
due to the fact that HLasso program includes a SNP in the
model if it significantly improves prediction of casecontrol status beyond that obtained from the SNP already
included. If there are two strongly correlated predictors,
and if the marginal increase is minimal, then the program
is inclined to choose only one of the two predictors.

The simultaneous analysis of SNPs confirmed several
previous findings of causal variants for RA: the HLADRB1 region of chromosome 6, the TRF1-C5 region on
chromosome 9, and the PTPN22 region on chromosome 1.
However, it did not confirm the findings on the PADI4
region on chromosome 1, known to be a causal variant
for RA [10].

Conclusion

We did not check for population stratification because
the samples were from Caucasian population, which is
expected to be relatively homogeneous. However, Sarasu
et al. [9] suggests that population stratification is present
in the data. The method we use seems to be reasonably
robust to population stratification because type I error is
well controlled. The SNP data had already been checked
for errors [11], and hence, no further checking for errors

The simultaneous analysis of all SNPs using HLasso
reduced considerably the overall probability for false
positives. The method confirmed many of the previous
findings by the single-SNP analysis.
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